RxDoctor Payments Data

Katrina Fernandez

Family · Cincinnati, OHNPI 1912307091

Payments from drug & device makers

$2,748in general payments, 2019–2025

Across 132 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$408
  • Lilly USA, LLC$207
  • Novo Nordisk$166
  • Abbott$156
  • Johnson & Johnson$146
  • plus $323 from 8 others

What the payments were for

  • Food & beverage$2,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,748 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$12,841
Medicare patients
35
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$55,352
TrulicityDulaglutide43$48,067
MounjaroTirzepatide26$26,664
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$16,030
JardianceEmpagliflozin13$14,594
FarxigaDapagliflozin Propanediol11$11,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,186
EliquisApixaban13$7,815
Breo ElliptaFluticasone/Vilanterol11$4,632
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,335
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$1,278
Albuterol Sulfate HfaAlbuterol Sulfate30$1,275
Ondansetron OdtOndansetron18$1,263
Rosuvastatin Calcium69$1,139
Varenicline Tartrate11$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$207$74,73169 claims
Novo NordiskOzempic$166$55,35248 claims
AstraZenecaBreztri Aerosphere, Farxiga$408$27,05837 claims
Boehringer IngelheimJardiance$28$14,59413 claims
GSKTrelegy Ellipta, Breo Ellipta$48$13,81825 claims
PfizerEliquis$51$7,81513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →